FibroGen (FGEN) Reaches $29.00 52-Week High; Centrais Eletricas Brasileiras S (EBR) Shorts Increased By 8.22%

Centrais Eletricas Brasileiras S (NYSE:EBR) had an increase of 8.22% in short interest. EBR’s SI was 248,800 shares in May as released by FINRA. Its up 8.22% from 229,900 shares previously. With 169,100 avg volume, 2 days are for Centrais Eletricas Brasileiras S (NYSE:EBR)’s short sellers to cover EBR’s short positions. The SI to Centrais Eletricas Brasileiras S’s float is 0.05%. The stock increased 2.16% or $0.12 on May 2, reaching $5.67. About 178,404 shares traded or 19.91% up from the average. Centrais Eletricas Brasileiras SA (ADR) (NYSE:EBR) has declined 7.19% since September 23, 2016 and is downtrending. It has underperformed by 17.52% the S&P500.

The stock of FibroGen Inc (NASDAQ:FGEN) hit a new 52-week high and has $31.61 target or 9.00% above today’s $29.00 share price. The 6 months bullish chart indicates low risk for the $1.92B company. The 1-year high was reported on May, 2 by Barchart.com. If the $31.61 price target is reached, the company will be worth $172.80M more. The stock increased 0.87% or $0.25 during the last trading session, reaching $29. About 751,765 shares traded or 42.69% up from the average. FibroGen Inc (NASDAQ:FGEN) has risen 29.74% since September 23, 2016 and is uptrending. It has outperformed by 19.41% the S&P500.

Analysts await FibroGen Inc (NASDAQ:FGEN) to report earnings on May, 8. They expect $-0.63 EPS, down 40.00% or $0.18 from last year’s $-0.45 per share. After $-0.54 actual EPS reported by FibroGen Inc for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.

FibroGen, Inc. is a science-based biopharmaceutical company. The company has market cap of $1.92 billion. The Firm is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. It currently has negative earnings. The Company’s lead product candidate is roxadustat .

Among 3 analysts covering FibroGen Inc (NASDAQ:FGEN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. FibroGen Inc has $40 highest and $25 lowest target. $34’s average target is 17.24% above currents $29 stock price. FibroGen Inc had 6 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Neutral”. The stock has “Buy” rating by Citigroup on Friday, December 4. The stock of FibroGen Inc (NASDAQ:FGEN) earned “Outperform” rating by Credit Suisse on Thursday, February 11. Citigroup initiated the stock with “Buy” rating in Wednesday, July 29 report. On Wednesday, September 23 the stock rating was initiated by Lake Street with “Hold”.